Barclays Maintains Equal-Weight on DexCom, Raises Price Target to $93
A Quick Look at Today's Ratings for DexCom(DXCM.US), With a Forecast Between $88 to $109
DexCom Price Target Cut to $90.00/Share From $100.00 by Piper Sandler
DexCom Is Maintained at Overweight by Piper Sandler
Citigroup Adjusts Price Target on DexCom to $82 From $80
BTIG Adjusts Price Target on DexCom to $109 From $107
Redburn Atlantic Adjusts DexCom Price Target to $110 From $115
DexCom Analyst Ratings
Baird Maintains Outperform on DexCom, Lowers Price Target to $105
Barclays Maintains DexCom(DXCM.US) With Hold Rating, Maintains Target Price $90
William Blair Maintains DexCom(DXCM.US) With Buy Rating
Analysts Offer Insights on Healthcare Companies: AptarGroup (ATR) and Dexcom (DXCM)
TD Cowen Maintains DexCom(DXCM.US) With Buy Rating, Maintains Target Price $100
Dexcom's Strong Q1 Performance and Strategic Initiatives Drive Buy Rating
Wells Fargo Maintains DexCom(DXCM.US) With Buy Rating, Maintains Target Price $98
Wells Fargo Sticks to Their Buy Rating for Dexcom (DXCM)
Wells Fargo Maintains DexCom(DXCM.US) With Buy Rating, Maintains Target Price $98
RBC Capital Maintains DexCom(DXCM.US) With Buy Rating, Cuts Target Price to $100
Wells Fargo Sticks to Its Buy Rating for Dexcom (DXCM)
BTIG Maintains DexCom(DXCM.US) With Buy Rating, Cuts Target Price to $107